Bechtel Medical announced in a November 10, 2026, press release that its Wound VOX system received 510(k) clearance from the US Food and Drug Administration. The company describes the device as the first cleared system combining negative pressure wound therapy (NPWT) and topical oxygen therapy.

According to the release, Wound VOX offers three operating modes: continuous NPWT, intermittent NPWT, and intermittent NPWT with adjunctive topical oxygen therapy. Bechtel Medical says integrating these capabilities into one platform may simplify the operational demands of using separate wound care technologies.

The release cites a 2025 systematic review and meta-analysis that evaluated 11 randomized controlled trials comparing combined NPWT and topical oxygen therapy with NPWT alone. According to the release, the analysis reported higher complete wound healing rates and lower bacterial positivity with combination treatment. The company explicitly notes that these findings came from studies of the treatment approaches and were not generated from clinical studies of Wound VOX.

Founder and CEO John Gvodas said the system was developed to simplify therapy delivery and address operational and economic barriers. Bechtel Medical plans a limited commercial release in December 2026, according to the announcement.

For information, including company contact details, read the full press release.